# OnCo record gallium (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/gallium/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "gallium", "NCT01332968" ;
  schema:name "GALLIUM"@en ;
  schema:alternateName "BO21223"@en ;
  schema:description "GALLIUM showed that the newer anti-CD20 antibody obinutuzumab kept follicular lymphoma at bay for longer than rituximab when given with chemotherapy and as maintenance, at the cost of more serious side effects, and it became a first-line option."@en ;
  schema:url <https://onco.cc/trials/gallium/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT01332968> ;
  onco:status "positive" ;
  onco:tag "soc-trials" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/follicular-lymphoma/>, <https://onco.cc/cancers/marginal-zone-lymphoma/>, <https://onco.cc/cancers/non-hodgkin-lymphoma/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/> ;
  onco:drugs <https://onco.cc/drugs/obinutuzumab/>, <https://onco.cc/drugs/rituximab/>, <https://onco.cc/drugs/bendamustine/>, <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/vincristine/>, <https://onco.cc/drugs/prednisone/> ;
  onco:companies <https://onco.cc/companies/roche-genentech/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-gallium-obinutuzumab-first-line-follicular-lymphoma-marcus-nejm-2017/> .